GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Radius Health Inc (NAS:RDUS) » Definitions » Shiller PE Ratio

Radius Health (Radius Health) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Radius Health Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Radius Health Shiller PE Ratio Historical Data

The historical data trend for Radius Health's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radius Health Shiller PE Ratio Chart

Radius Health Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Radius Health Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Radius Health's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Radius Health's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radius Health's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Radius Health's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Radius Health's Shiller PE Ratio falls into.



Radius Health Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Radius Health's E10 for the quarter that ended in Jun. 2022 is calculated as:

For example, Radius Health's adjusted earnings per share data for the three months ended in Jun. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2022 (Change)*Current CPI (Jun. 2022)
=-0.27/125.0168*125.0168
=-0.270

Current CPI (Jun. 2022) = 125.0168.

Radius Health Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201209 -2.169 97.633 -2.777
201212 -2.508 96.871 -3.237
201303 -0.854 98.209 -1.087
201306 -2.456 98.518 -3.117
201309 -2.092 98.790 -2.647
201312 -3.086 98.326 -3.924
201403 -0.672 99.695 -0.843
201406 -2.220 100.560 -2.760
201409 -0.590 100.428 -0.734
201412 -0.550 99.070 -0.694
201503 -0.470 99.621 -0.590
201506 -0.610 100.684 -0.757
201509 -0.680 100.392 -0.847
201512 -0.770 99.792 -0.965
201603 -0.940 100.470 -1.170
201606 -1.010 101.688 -1.242
201609 -1.070 101.861 -1.313
201612 -1.220 101.863 -1.497
201703 -1.320 102.862 -1.604
201706 -1.580 103.349 -1.911
201709 -1.310 104.136 -1.573
201712 -1.590 104.011 -1.911
201803 -1.370 105.290 -1.627
201806 -1.520 106.317 -1.787
201809 -1.090 106.507 -1.279
201812 -0.900 105.998 -1.061
201903 -0.940 107.251 -1.096
201906 -0.770 108.070 -0.891
201909 -0.650 108.329 -0.750
201912 -0.540 108.420 -0.623
202003 -0.810 108.902 -0.930
202006 -0.950 108.767 -1.092
202009 -0.140 109.815 -0.159
202012 -0.460 109.897 -0.523
202103 -0.340 111.754 -0.380
202106 -0.350 114.631 -0.382
202109 -0.470 115.734 -0.508
202112 -0.330 117.630 -0.351
202203 -0.390 121.301 -0.402
202206 -0.270 125.017 -0.270

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Radius Health  (NAS:RDUS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Radius Health Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Radius Health's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Radius Health (Radius Health) Business Description

Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
Executives
Willard H Dere director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jean Pierre Garnier director UNITED TECHNOLOGIES CORP, 10 FARM SPRINGS ROAD, FARMINGTON CT 06032
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
G. Kelly Martin director, officer: CEO and President C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Sean Murphy director C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Elizabeth Messersmith officer: Senior Vice President 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Danielle Holtschlag officer: Vice President, Sales 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Chhaya Shah officer: Chief Business Officer 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Susan Vissers Lisa director 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000